The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This research study has been designed to test whether a drug called trientine dihydrochloride
(also called Cufence) reduces heart muscle thickening, improves exercise capacity, improves
heart function and reduces abnormal heart rhythms in patients with hypertrophic
cardiomyopathy (HCM). The study is also assessing how trientine works in HCM. Participants
will be prescribed either trientine or placebo, for a period of 12 months.
Phase:
Phase 2
Details
Lead Sponsor:
Manchester University NHS Foundation Trust
Collaborators:
National Institute for Health Research, United Kingdom Univar BV University of Liverpool University of Manchester University of Oxford